ALT: How to Interpret Your Result

What ALT Actually Measures

ALT is an intracellular enzyme concentrated primarily in hepatocytes. When liver cells sustain damage, their membranes become permeable, and ALT leaks into the bloodstream [1]. Your lab report captures that leakage as a number in units per liter (U/L). The enzyme also exists in smaller amounts in kidney, cardiac, and skeletal muscle tissue, but the liver contains roughly 3,000 times more ALT per gram of tissue than any other organ [2]. That concentration makes ALT the most liver-specific of the commonly ordered aminotransferases.

A single ALT reading is a snapshot. It tells you whether hepatocytes were injured around the time of the draw, not whether chronic damage has occurred. Serial measurements over weeks or months provide far more clinical value than an isolated number. Dr. Anna Mae Diehl, a hepatologist at Duke University, has stated: "One ALT value is a photograph; a trend line is the movie. Clinicians should resist the urge to act on a single frame." The enzyme's half-life in serum is roughly 47 hours, meaning that a reading taken today largely reflects events from the past two to four days [3].

Normal ALT Ranges and Why They Vary

Standard reference ranges at most U.S. laboratories list the upper limit of normal (ULN) at 35 U/L for women and 40 U/L for men [4]. Those thresholds date from population studies that included individuals with undiagnosed liver disease, which inflated the "normal" ceiling.

A landmark 2002 study by Prati and colleagues, published in the Annals of Internal Medicine, recalculated healthy ALT cutoffs after excluding donors with hepatitis C, metabolic syndrome, and heavy alcohol use. The revised ULN dropped to 19 U/L for women and 30 U/L for men [5]. The American College of Gastroenterology (ACG) endorsed these lower thresholds in its 2017 clinical guideline on evaluation of abnormal liver chemistries [6]. The American Association for the Study of Liver Diseases (AASLD) echoed the recommendation in its 2023 MASLD practice guidance [7].

Why does this matter for your result? A reading of 34 U/L in a woman might sit inside the laboratory's printed reference range yet exceed the evidence-based cutoff by 79%. If your result falls between the Prati threshold and the lab's printed ULN, a conversation with your clinician about MASLD screening, alcohol intake, and medication review is reasonable.

Age, sex, and body mass index also influence baseline ALT. Levels tend to peak in men between ages 20 and 45, then decline. In women, ALT tends to rise modestly after menopause [8]. Children and adolescents carry their own pediatric reference intervals.

What a High ALT Means

An elevated ALT signals hepatocyte injury. The degree of elevation helps narrow the differential diagnosis.

Mild elevation (1 to 5x ULN). The most frequent cause worldwide is MASLD, present in an estimated 30% of the global adult population according to a 2023 meta-analysis in Hepatology (N=8,515,431) [9]. Other common causes include chronic hepatitis B or C infection, alcohol-associated liver disease, medication-induced liver injury (DILI), and autoimmune hepatitis. Statin therapy can raise ALT modestly in 0.5% to 2% of patients, though the ACG guideline notes this rarely requires discontinuation [6]. Supplements containing green tea extract, kava, and high-dose vitamin A are under-recognized contributors.

Moderate elevation (5 to 10x ULN). This range raises concern for acute viral hepatitis, ischemic hepatitis, Budd-Chiari syndrome, and Wilson disease. Acetaminophen toxicity at doses exceeding 4 g/day can push ALT into this zone rapidly [10].

Severe elevation (greater than 10x ULN). Values above 1,000 U/L occur in acetaminophen overdose, ischemic hepatitis from shock or heart failure, and acute viral hepatitis A or B. A 2019 retrospective cohort at Mayo Clinic (N=1,116) found that ischemic hepatitis accounted for 39% of cases with ALT above 10x ULN, followed by drug-induced injury at 23% [11].

The ALT-to-AST ratio offers additional diagnostic texture. An AST/ALT ratio greater than 2:1 in the setting of elevation suggests alcohol-associated liver disease, while a ratio below 1:1 is more typical of MASLD or viral hepatitis [6]. This ratio loses reliability when ALT exceeds 300 U/L because both enzymes become markedly elevated.

What a Low ALT Means

Low ALT receives far less clinical attention than elevation. Values below 7 U/L are uncommon but not automatically pathological. A few scenarios explain low readings.

Pyridoxal phosphate (vitamin B6) serves as a cofactor for ALT. Deficiency of B6 can suppress measurable enzyme activity, producing artificially low results [12]. This mechanism is relevant in chronic alcohol use disorder, malnutrition, and patients on isoniazid therapy. Correcting the B6 deficit normalizes the assay.

Some studies have linked very low ALT to sarcopenia and frailty in older adults. A 2021 analysis in the Journal of Cachexia, Sarcopenia and Muscle (N=5,128) found that ALT below 12 U/L in adults over age 65 independently predicted all-cause mortality (hazard ratio 1.38, 95% CI 1.12 to 1.70) [13]. The proposed mechanism: ALT partly reflects hepatic and muscle protein turnover, so very low activity may indicate diminished lean mass.

For most healthy adults under 65, a low ALT is reassuring. It simply means hepatocytes are intact and leaking minimal enzyme.

How ALT Fits into a Complete Liver Panel

ALT is rarely ordered in isolation. A standard hepatic function panel bundles ALT with AST, alkaline phosphatase (ALP), total and direct bilirubin, albumin, and total protein [4]. Each analyte probes a different aspect of liver physiology.

ALT and AST together characterize hepatocellular injury. ALP and gamma-glutamyl transferase (GGT) characterize cholestatic or biliary injury. Bilirubin and albumin reflect the liver's synthetic and excretory capacity. A pattern of isolated ALT elevation with normal ALP and bilirubin points toward hepatocellular damage without bile duct obstruction.

The R-ratio, calculated as (ALT / ULN of ALT) divided by (ALP / ULN of ALP), formalizes this distinction [14]. An R-ratio above 5 indicates hepatocellular injury. Below 2 indicates cholestatic injury. Between 2 and 5 is mixed. This calculation is standard practice in evaluating suspected drug-induced liver injury per the Roussel Uclaf Causality Assessment Method (RUCAM) framework.

Platelet count and the FIB-4 index add a fibrosis dimension. FIB-4 combines age, ALT, AST, and platelet count into a single score that stratifies fibrosis risk. A FIB-4 below 1.30 has a negative predictive value above 90% for advanced fibrosis, allowing clinicians to avoid liver biopsy in many patients [15]. The AASLD's 2023 MASLD guidance recommends FIB-4 as the first-line non-invasive fibrosis assessment [7].

How to Lower Elevated ALT

Lowering ALT means treating the underlying cause of hepatocyte injury, not suppressing the enzyme itself. The enzyme is the smoke alarm. Turn it off without finding the fire and you gain nothing.

MASLD and metabolic risk. Weight loss of 5% to 7% of body weight reliably reduces ALT in MASLD. The PIVENS trial (N=247) demonstrated that vitamin E at 800 IU daily lowered ALT by a mean of 37 U/L over 96 weeks compared to 20 U/L with placebo in non-diabetic adults with biopsy-confirmed non-alcoholic steatohepatitis (NASH) [16]. Pioglitazone 30 mg daily produced similar biochemical improvement in the same trial. In March 2024, the FDA approved resmetirom (Rezdiffra) for NASH with moderate to advanced fibrosis, the first drug specifically indicated for that population [17].

Alcohol reduction. Even modest decreases in consumption produce rapid ALT normalization. A controlled trial in The BMJ (N=97) found that abstaining from alcohol for one month reduced ALT by a median of 12.5% [18].

Medication review. Acetaminophen, amiodarone, methotrexate, isoniazid, and certain anticonvulsants are well-documented causes of ALT elevation. Dose adjustment or substitution under clinician guidance typically resolves the abnormality within four to eight weeks.

Exercise. Aerobic exercise at 150 minutes per week reduces intrahepatic fat by 2% to 4% absolute points independent of weight loss, per a 2023 meta-analysis in the Journal of Hepatology (N=1,634) [19]. Resistance training adds benefit by increasing muscle mass, which may stabilize the ALT-to-lean-mass ratio.

Coffee. Epidemiological data consistently associate coffee consumption with lower ALT. A pooled analysis of nine cohorts (N=432,133) found that three or more cups per day was associated with a 21% lower odds of elevated ALT (OR 0.79, 95% CI 0.71 to 0.87) [20]. The mechanism appears to involve kahweol and cafestol reducing hepatic oxidative stress, though randomized trial data remain limited.

When to Recheck and When to Escalate

The ACG guideline provides a practical algorithm [6]. For mild ALT elevation (1 to 5x ULN) identified incidentally, repeat the test in three to six months after addressing modifiable risk factors such as alcohol intake, weight, and hepatotoxic supplements. If the elevation persists, order hepatitis B surface antigen, hepatitis C antibody, iron studies, and an autoimmune panel (ANA, anti-smooth muscle antibody, IgG).

Persistent unexplained elevation beyond six months warrants hepatology referral. ALT above 10x ULN requires same-day evaluation, including acetaminophen level, prothrombin time/INR, and imaging. A rising INR alongside ALT above 1,000 U/L raises concern for acute liver failure, which carries a mortality rate exceeding 40% without transplantation according to the Acute Liver Failure Study Group registry [21].

The frequency of monitoring depends on the clinical context. Patients starting methotrexate or isoniazid typically have ALT checked at baseline, monthly for the first three months, then every three to six months. Patients with stable MASLD and low FIB-4 can be rechecked annually.

ALT in Specific Populations

Pregnancy. ALT normally decreases in the first and second trimesters due to hemodilution, then returns to pre-pregnancy levels in the third trimester. New ALT elevation in the third trimester should prompt evaluation for HELLP syndrome, intrahepatic cholestasis of pregnancy, and acute fatty liver of pregnancy [22].

Pediatric patients. The SAFETY study (Schwimmer et al., JAMA 2006, N=742) established that an ALT above 25 U/L in boys and 22 U/L in girls should trigger screening for pediatric MASLD [23]. Childhood obesity has made this the most common chronic liver disease in children.

Patients on GLP-1 receptor agonists. Semaglutide and tirzepatide both reduce ALT in patients with MASLD. In the STEP 1 trial (N=1,961), semaglutide 2.4 mg weekly reduced ALT by a mean of 5.3 U/L at 68 weeks compared to a 0.2 U/L increase with placebo [24]. The SURPASS-3 MRI substudy showed that tirzepatide 15 mg reduced liver fat by 8.1 percentage points versus 1.7 with insulin degludec [25]. These reductions in liver fat track directly with ALT normalization.

Patients on testosterone replacement therapy (TRT). Oral methyltestosterone historically caused cholestatic liver injury, but modern injectable and transdermal testosterone formulations carry minimal hepatotoxicity. The Endocrine Society's 2018 guideline recommends checking hepatic function at baseline but does not require routine ALT monitoring during TRT with non-oral formulations [26].

Limitations of ALT as a Biomarker

ALT is sensitive for hepatocellular injury but not specific for any single disease. It does not measure liver function. A cirrhotic liver with extensive fibrosis can have a normal or even low ALT because few healthy hepatocytes remain to leak enzyme [27]. Dr. Robert Gish, a hepatologist affiliated with Stanford University, has noted: "Normal ALT does not mean normal liver. Patients with cirrhosis sometimes have the most reassuring-looking lab panels."

ALT also does not stage fibrosis. Two patients with identical ALT values of 55 U/L can have wildly different histology: one with simple steatosis and no fibrosis, the other with bridging fibrosis approaching cirrhosis. That gap is why non-invasive fibrosis tools like FIB-4, elastography, and the Enhanced Liver Fibrosis (ELF) test exist [7].

Muscular injury from intense exercise can transiently raise ALT by 2x to 3x, particularly after eccentric or resistance training, because skeletal muscle contains a small amount of the enzyme [28]. Repeating the test after 48 to 72 hours of rest clarifies the source.

Your ALT result is one data point inside a larger clinical picture. Interpret it alongside your full hepatic panel, medical history, medication list, and imaging when warranted. If your result exceeds 19 U/L (women) or 30 U/L (men) on the updated Prati thresholds, ask your clinician whether MASLD screening with FIB-4 is appropriate.